Fully enclosed cancer

Don't just focus on the technique, any technique.

focus on the depth of experience of he who applies the therapy, be it nano knife or radical surgery or something else.

Ive posted this before, but you may have missed it- Your cancer specialists are in the best position to answer questions because  each of us has distinctly different conditions- i.e. your age,  country of origin, past history, health, previous health issues, etc. The machine you mention is an external beam radiation device, one of many on the market. Usuallt EBRT is just a part of the overall therapy program. In the US, Harvard Medical and the National Cancer Society have published guidelines and pamphlets available online. The latest research and standards are also published online. Below, Ive extracted a portion of the new guidelines. These are for men in the low to intermediate cancer risk, based on your therapist's interpretation of data.

Table 2: Boosting the effectiveness of radiation therapy

A randomized controlled study involving 206 men with early-stage prostate cancer evaluated whether adding six months of hormone therapy to external-beam radiation treatment would boost both overall survival and disease-free survival (meaning that the men did not suffer a relapse). The results are given below. The same research group found, in an earlier study, that the addition of hormone therapy was of most benefit to men who were considered at moderate or high risk, based on their clinical profile.

Five-year follow-up Radiation treatment alone Radiation treatment and hormone therapy

Percentage of men who survived 78% 88%

Percentage of men who avoided relapse 57% 82%

Source: Journal of the American Medical Association, 2004;292:821–7. PMID: 15315996.

Combined with radiation therapy. A number of studies have shown that men with early-stage prostate cancer are more likely to be cured when hormone therapy is given in conjunction with radiation therapy (see Table 2 above for the results of one study). Even when the disease is regionally advanced, meaning that it has progressed to tissues immediately surrounding the prostate gland, neoadjuvant hormone therapy reduces risk of progression and relapse (see “Evidence for combining hormone therapy and radiation treatment”).

See harvardprostateknowledge dot org for the complete discussion by Dr Marc B. Garnick, M.D.,from Harvard Medical.

Another resource is the American Society of Radiation Oncology. They recently published the results of an enhanced study of patients with low to intermediate prostate cancer. Here is an excerpt:

Ten-year findings from the trial indicate that for men with early stage prostate cancer, there is no difference in mortality rates following active monitoring, surgery or RT, and moreover, that cancer-specific deaths at ten years following diagnosis averaged only one percent for all men enrolled in the trial.

Growth of the cancer outside of the prostate did vary between monitoring and treatment groups. Rates of both regional spread and distant metastases were significantly higher for men who were monitored rather than treated for their early stage disease. Progression did not vary, however, between the surgery and RT groups, although patients in the trial reported different side effects with each modality.

“These findings underscore the essential role of dialogue in treatment selection,” said ASTRO President David C. Beyer, MD, FASTRO. “Men with prostate cancer are all different, and the relative costs and benefits associated with the multiple options to treat it can vary substantially between individuals. The best treatment decisions for prostate cancer, or any cancer, take into consideration the specifics of each individual patient’s disease, expectations and preferences. These options can be confusing, and patients should always make these decisions after consultation with a radiation oncologist and urologist”

Best of luck in your therapy.